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Cyclo-oxygenase (COX)-2 is induced in various types of cancer tissues. Here, we demonstrate stromal expression of both COX-2
and microsomal prostaglandin E2 synthase (mPGES)-1 in gastrointestinal hamartomas developed in Lkb1
þ/ , Smad4
þ/  and Cdx2
þ/ 
mice. These results suggest that PGE2 produced by COX-2 and mPGES-1 plays an important role in hamartoma development
regardless of the mutated genes causing hamartomas.
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Using Apc
D716 mouse mutant, a model for familial adenomatous
polyposis (FAP), we demonstrated earlier that disruption of the
gene encoding cyclo-oxygenase (COX)-2 or prostaglandin E2
(PGE2) receptor EP2 suppresses intestinal polyposis (Oshima
et al, 1996; Sonoshita et al, 2001). These results indicate that PGE2
produced through the COX-2 pathway plays an important role in
intestinal tumorigenesis. One of the PGE2 synthases, microsomal
prostaglandin E2 synthase (mPGES)-1 appears to be responsible
for PGE2 production in tumour tissues, because this enzyme is
induced and functionally coupled with COX-2 in a human
embryonic kidney cell line (Murakami et al, 2000). Likewise,
COX-2 and mPGES-1 are induced simultaneously in human
colorectal cancer tissues (Yoshimatsu et al, 2001), intestinal-type
gastric adenocarcinomas (Van Rees et al, 2003) and Apc
D716 mouse
intestinal adenomas (Takeda et al, 2003).
Peutz–Jeghers syndrome (PJS) and juvenile polyposis syndrome
(JPS) are autosomal dominant diseases characterised by hamarto-
matous polyps of the gastrointestinal tract with an increased risk
of cancer development. Germ line mutations in the LKB1
(Hemminki et al, 1998; Jenne et al, 1998) and SMAD4 (Howe
et al, 1998) are responsible for subpopulations of PJS and JPS,
respectively. Gene-targeted mice heterozygous for Lkb1 and Smad4
develop gastrointestinal hamartomas that have histological char-
acteristics similar to those of PJS and JPS, respectively (Takaku
et al, 1999; Miyoshi et al, 2002). Recently, it has been reported that
COX-2 expression is induced in hamartomatous polyps of PJS
patients and Lkb1
þ/  mice (Rossi et al, 2002; de Leng et al, 2003;
McGarrity et al, 2003), suggesting the roles of COX-2 in
hamartoma development. However, COX-2 expression in other
types of hamartomas has not yet been examined. Furthermore, it is
important to determine whether the expression of mPGES-1 is also
induced in hamartoma tissues as in intestinal adenomas and
carcinomas.
Here we show that both COX-2 and mPGES-1 are induced in
gastric hamartoma tissues of Lkb1
þ/  and Smad4
þ/  mice.
In addition, we demonstrate induction of these enzymes also in
Cdx2
þ/  mouse colonic hamartomas. These results strongly
suggest that production of PGE2 is responsible for gastrointestinal
hamartoma development as in intestinal adenomatous polyposis.
MATERIALS AND METHODS
All in vivo experiments were carried out with ethical committee
approval and met the standards required by the UKCCCR
guidelines (Workman et al, 1998). Constructions of Lkb1
þ/ ,
Smad4
þ/  and Cdx2
þ/  mutant mice have been described
previously (Takaku et al, 1999; Tamai et al, 1999; Miyoshi et al,
2002). We used these mouse models to examine the expression
patterns of COX-1, COX-2 and mPGES-1 in hamartomas that were
caused by mutations in the putative genes, Lkb1, Smad4 and Cdx2,
respectively. As the expression of COX-2 and mPGES-1 can be
affected by various conditions such as infections, inflammations
and host immune responses, it is important to use congenic mice
bred in a specific pathogen-free (SPF) facility and compare them
with the age-matched littermate controls. The results from these
mouse experiments should provide important pieces of evidence
applicable to human clinical research. Ages of mutant mice used in
this study were 60–66, 76–90 and 20–35 weeks for Lkb1
þ/ ,
Smad4
þ/  and Cdx2
þ/ , respectively. Hamartomas were sampled
from seven independent mice and used for further analysis.
For immunoblotting, tissue samples were homogenised and
sonicated in lysis buffer (50mM phosphate buffer pH 7.0, 100mM
NaCl, 2mM EDTA) containing a protease inhibitor cocktail (Roche
Diagnostics, Nonnenwald, Penzberg, Germany). After centrifuga-
tion at 10000 g at 41C for 10min, 40mg of the supernatant
protein was mixed with 6 SDS sample buffer (350mM Tris-HCl,
pH 6.8, 36% glycerol, 10% SDS, 600mM DTT), separated in SDS–
polyacrylamide gels and transferred onto PVDF membranes. After
blocking with 5% skimmed milk/Tris-buffered saline/Tween 20,
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smembranes were incubated with an antibody for COX-1 (Santa
Cruz Biotechnology, Santa Cruz, CA, USA), COX-2, cPGES or
mPGES-1 (Cayman Chemical, Ann Arbor, MI, USA) at 1000-fold
dilution, or for b-actin (Sigma) at 5000-fold dilution. The ECL
detection system (Amersham Pharmacia, Uppsala, Sweden) was
used to detect the signals.
For immunohistochemistry, tissue samples were fixed in 4%
paraformaldehyde, embedded in paraffin wax and sectioned at
4mm. After pretreatment in 3% H2O2 in methanol, sections were
boiled in 10mM citrate buffer (pH 6.0) in a microwave oven for
5min. Sections were blocked with 3% BSA-10% normal serum for
1h and incubated with the primary antibody for COX-1, COX-2 or
mPGES-1 at 400-fold dilution. Immunostaining signals were
visualised using Vectastain Elite Kit (Vector Laboratories,
Burlingame, CA, USA).
RESULTS AND DISCUSSION
Hamartomatous polyp tissues were excised from the stomach of
Lkb1
þ/  and Smad4
þ/  mice and from the colon of Cdx2
þ/ 
mice. We first examined the expression levels of COX enzymes and
PGE2 synthases in these tumour tissues by immunoblotting
(Figure 1). The expression of COX-2 and mPGES-1 was detected
in all hamartomatous polyps, whereas these enzymes were rarely
expressed in the normal tissues. On the other hand, COX-1 and
cPGES were detected in both normal and hamartoma tissues.
These results are consistent with our recent report that COX-1 and
cPGES are expressed constitutively in the normal mouse intestines,
whereas COX-2 and mPGES-1 are induced in the intestinal polyps
of Apc
D716 mice (Takeda et al, 2003).
We next determined by immunohistochemistry the localisation
of COX-1, COX-2 and mPGES-1 in the hamartoma tissues of the
Lkb1
þ/ , Smad4
þ/  and Cdx2
þ/  mice, respectively (Figure 2). In
COX-2
COX-1
mPGES-1
cPGES
Lkb1+/- Smad4+/- Cdx2+/-
β-actin
NP NP N P
Figure 1 Immunoblotting analysis of COX-1, COX-2, cPGES and
mPGES-1 in the normal and polyp tissues. N, normal stomach (Lkb1
þ/ ,
Smad4
þ/ ) or intestine (Cdx2
þ/ ); P, hamartomatous polyp.
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Figure 2 Immunohistochemical analysis of COX-1, COX-2 and mPGES-1 in hamartomas. Expression of COX-1 (A, D, G), COX-2 (B, E, H) and
mPGES-1 (C, F, I) in hamartomatous polyps of Lkb1
þ/  (A–C), Smad4
þ/  (D–F) and Cdx2
þ/  (G–I) mice, respectively. Bars; 50mm.
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sall samples, COX-1 was expressed in the stromal cells of
hamartomas (Figure 2A,D,G) as well as in those of the normal
mucosa (data not shown). Expression of COX-2 and mPGES-1 was
detected in the stroma of hamartomas near the intestinal lumen,
overlapping partly with the COX-1-expressing cells (Figure 2B–I).
Moreover, cells expressing COX-2 and mPGES-1 appeared to be
the same stromal cells showing a fibroblast-like morphology.
There was no apparent difference in the expression patterns of
COX-1, COX-2 and mPGES-1 among the hamartomas developing
in different mutants. We did not find any difference in the
expression levels and cell types among the individual mice of each
model. These results indicate that COX-2 and mPGES-1 are
induced in the stromal cells, and are consistent with our recent
results with the intestinal adenomas in Apc
D716 mice (Takeda et al,
2003). Namely, COX-2 and mPGES-1 are induced simultaneously
in the COX-1-expressing stromal fibroblasts. Given that COX-2
and mPGES-1 are functionally coupled (Murakami et al, 2000),
PGE2 levels in the hamartomas should be elevated significantly by
simultaneous induction of both enzymes from the basal level that
is secured by the COX-1 pathway alone. Although CDX2 mutations
have not been detected in any hereditary hamartoma syndromes, it
is conceivable that a subset of sporadic hamartomas contains
CDX2 mutations. Regardless of the mutated genes that caused
hamartomas, stromal PGE2 production appears to play a key role
in the hamartoma expansion.
The PGE2 signalling stimulates tumour angiogenesis through the
EP2 receptor (Seno et al, 2002), increases cell survival and motility
(Sheng et al, 2001), inhibits host immune responses (Huang et al,
1998) and activates epidermal growth factor receptor (EGFR) (Pai
et al, 2002). Accordingly, it is conceivable that stromal PGE2 in the
hamartomas contributes to tumour expansion through these
effects.
Inhibition of COX-2 by NSAIDs or COX-2-selective inhibitors
suppresses intestinal polyposis in Apc
D716 mice and FAP patients
(Oshima et al, 1996; Steinbach et al, 2000). In addition,
administration of COX-2 inhibitor to trefoil factor 1 (TFF1)-
deficient mice suppresses gastric adenomas that are caused
without Wnt signalling activation (Saukkonen et al, 2003). The
results suggest that COX-2 induction in the tumour stroma is
independent of the molecular mechanism that initiates tumorigen-
esis in the epithelial cells. These results, taken together, strongly
suggest that COX-2 inhibitors, and possibly EP antagonists, are
therapeutic agents effective for not only adenomatous polyposis
but also hamartomas of the gastrointestinal tract. As hamartoma-
tous polyps can progress into neoplastic tumours (Wang et al,
1999), COX-2 inhibitors may also turn out to be cancer
chemopreventive agents suitable for hereditary hamartoma
syndromes.
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